Objective To clarify the comprehensive clinical value, advantages, characteristics and therapeutic positioning of Ningmitai Capsules (宁泌泰胶囊) in the treatment of chronic prostatitis (damp-heat accumulation syndrome), and to provide references for decision-making of national medical and health administrative departments and rational clinical drug use. Methods An evaluation system was constructed based on the “6 + 1” dimensions of safety, effectiveness, economy, innovation, suitability, accessibility, and traditional Chinese medicine (TCM) characteristics. Multi-source evidence including questionnaire surveys, official website data, secondary evaluation of literature, and real-world data was integrated. The multi-criteria decision analysis (MCDA) model was used to measure each dimension, and the total value score was calculated based on TCM clinical evidence using software CSCv2.0. Results Ningmitai Capsules were rated Grade A for both safety and effectiveness (no serious adverse reactions, significant effects in anti-infection, relieving pain and alleviating urinary abnormalities); Grade B for economy, innovation, suitability, accessibility, and TCM characteristics (supported by economic evidence, obtained 1 invention patent, high acceptance among target populations, good resource accessibility, and a unique Miao medicine formula); the comprehensive evaluation of clinical value was Grade A. Conclusion Ningmitai Capsules have significant clinical value in the treatment of chronic prostatitis. It is recommended to further conduct pharmacological mechanism research and high-quality evidence-based research, optimize the production process, improve the drug insert, and give full play to its clinical advantages.

Ningmitai Capsules  /  chronic prostatitis  /  comprehensive clinical evaluation  /  multi-criteria decision analysis  /  safety  /  effectiveness  /  pharmacoeconomics